Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?

HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET.

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen's 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET.

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share. All of the shares sold in the offering were sold by Celldex. The gross proceeds to Celldex from this offering were approximately $460.5 million, excluding underwriting discounts and commissions and other offering-related expenses.

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters' option, if any, of approximately $400.4 million, excluding underwriting discounts and commissions and other offering-related expenses. The offering is expected to close on or about March 5, 2024, subject to customary closing conditions.

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?

The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Celldex (CLDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know

HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock are being offered by the Company. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.56 per share a year ago.

Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates

- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment nearing completion in Phase 2 CIndU study; Data expected 2H 2024 - - Phase 2 PN study expected to start in early 2024; Positive Phase 1 PN data reported in oral presentation at WCI 2023 -

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid onset within 2 weeks - - Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action - - Favorable safety profile - - 52 week results and Phase 3 CSU trial initiations anticipated in 2024 - - Company to host webcast February 25th at 9:45 am ET-

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 9:00 a.m. ET.

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2024 being held in Washington, DC on February 23-26, 2024. Abstracts will be available on the meeting website today, February 5, 2024.

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

Cullen/Frost Bankers

Chord Energy Corp

CNH Industrial NV

Crocs

CTO Realty Growth

Corning

Centrus Energy

Charles Schwab

MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.

MoneyShow's Best Investment Ideas For 2024: Part 3

Arista Networks

Baxter

Brookfield Infrastructure Partners L.P.

Blackrock Inc

BYD Company Limited

BYD Co Ltd

Cameco

Caesarstone

MoneyShow's Best Investment Ideas For 2024: Part 2

HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th at 5:05 pm ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

Pulmonx

Poseida Therapeutics

The article embarks on a transformative journey through the biotech frontier, where the listed companies stand as titans reshaping healthcare norms. The first one's strategic collaboration with a multinational healthcare giant propels financial strength, unlocking accelerated milestones in key programs.

Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare

Positive results achieved from phase 1b study using barzolvolimab for the treatment of patients with prurigo nodularis; Phase 2 multi-dose study to be initiated in early 2024. Positive results from a phase 2 study using barzolvolimab for the treatment of patients with chronic spontaneous urticaria achieved; CSU program ready for phase 3 study advancement. Goal to advance use of barzolvolimab for other mast cell disorder indications like eosinophilic esophagitis.

Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic

HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shares of its common stock at a public offering price of $27.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,113,750 shares of common stock at the public offering price, less underwriting discounts and commissions.

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

A leading pipeline drug did very well in phase 2 clinical testing. Barzolvolimab met its primary endpoint, and was generally well tolerated.

Why Celldex Therapeutics Blasted 13% Higher on Monday

Celldex could rival a key Regeneron drug, an analyst said Monday as CLDX stock rocketed on the results of multiple studies.

Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi

Celldex Therapeutics CLDX, +8.20% shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset in both chronic hives and an inflammatory skin disease.

Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions

-Barzolvolimab met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups- -Mean change from baseline to week 12 in UAS7 of -23.87 in 300 mg q8w dose group and -23.02 in 150 mg q4w dose group- -Barzolvolimab was generally well tolerated with a favorable safety profile- -Treatment will continue to 52 weeks; results support further development of barzolvolimab in Phase 3 CSU studies- - Company to host webcast call today at 8:00 am ET-

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

- Response observed as early as week 1 and durable for up to 16 weeks - - Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications - - Phase 2 PN study to initiate in early 2024 - - Conference call to be held on Monday, November 6 th at 8:00 am ET to discuss study results -

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

- Phase 2 CSU enrollment complete; topline data by YE 2023 - - Phase 1b PN data accepted at World Congress on Itch -

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

News for Celldex Therapeutics Stock (CLDX)